Treat-To-Target and Treat-To-Budget in Rheumatoid Arthritis: Measuring the Value of Individual Therapeutic Interventions

• Published in: Rheumatology and therapy. Vol. 6; no. 4; pp. 473 - 477
• Main Authors: Sacristán, José A., Díaz, Silvia, de la Torre, Inmaculada, Inciarte-Mundo, José, Balsa, Alejandro
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.12.2019; Springer Nature B.V; Adis, Springer Healthcare
• Subjects: Commentary; Cost control; DMARDs; Family Medicine; General Practice; Internal Medicine; Medicine; Medicine & Public Health; Orthopedics; Quality of Life Research; Rheumatoid arthritis; Rheumatology; Tapering; Treat-to-target; Value; Tapering; Value; Treat-to-target; DMARDs; Rheumatoid arthritis
• ISSN: 2198-6576; 2198-6584
• DOI: 10.1007/s40744-019-00178-3

Treat-to-target (T2T) and dose tapering after obtaining the therapeutic objective (called “treat-to-budget”-T2B-in this Commentary) are the two most commonly used therapeutic strategies in rheumatoid arthritis. In theory, both strategies could add value to the healthcare system, although they are focused on different objectives: T2T strategy improves outcomes but increases short-term costs, while the cost savings obtained through T2B are associated with higher relapse rates. The systematic implementation of both strategies must be founded on solid evidence of their effectiveness and efficiency. However, the level of evidence between guidelines and individual studies is inconsistent for both strategies and the number and the quality of cost-effectiveness analyses is scarce. Raising the level of evidence requires a move from generalization to individualization by conducting randomized clinical trials that assess each of the many strategies that fall under the umbrella of the overall T2T and T2B concepts. In addition, such studies should consider the therapeutic goals and impact of the disease from the perspective of individual patients, which is only possible by promoting shared decision-making. Funding Lilly Spain.